Approach to hypertrophic cardiomyopathy

被引：3

作者：

Autore C. ^{[1
]}

Spirito P. ^{[1
]}

机构：

[1] Divisione di Cardiologia, Ente Ospedaliero Ospedali Galliera, Genoa 16128

来源：

Current Treatment Options in Cardiovascular Medicine | 2004年 / 6卷 / 6期

关键词：

Verapamil; Sudden Death; Infective Endocarditis; Hypertrophic Cardiomyopathy; Disopyramide;

D O I：

10.1007/s11936-004-0006-7

中图分类号：

学科分类号：

摘要：

Hypertrophic cardiomyopathy is a genetic disease characterized by marked left ventricular (LV) hypertrophy. A dynamic LV outflow obstruction is present in approximately 20% of patients. Many affected individuals remain asymptomatic throughout life, others develop heart failure symptoms or atrial fibrillation (AF), and some die suddenly, often young and in the absence of previous symptoms. Stratification of sudden death risk is based on several markers, including a previous cardiac arrest, sustained ventricular tachycardia, family history of sudden death, extreme LV hypertrophy (≥ 30 mm), syncope, nonsustained ventricular tachycardia on Holter, and abnormal exercise blood pressure response. The implantable cardioverter-defibrillator is the most effective treatment for sudden death prevention, and should be considered in patients with either one strong or multiple risk factors. Important symptoms of heart failure develop in a minority of patients, largely is a consequence of diastolic dysfunction, and are usually treated with β blockers, or verapamil. In patients with LV obstruction and severe symptoms unresponsive to medications, myectomy operation or alcohol septal ablation is indicated for relieving the gradient and improving quality of life. AF develops in approximately 20% of patients. Amiodarone is the most effective medication for preventing AF recurrences. In chronic AF, β blockers or verapamil are usually effective for heart rate control. The threshold for, anticoagulants is low, because even brief AF episodes have a substantial embolization risk. Copyright © 2004 by Current Science Inc.

引用

页码：489 / 498

页数：9

共 30 条

[1] Wigle E.D., Rakowski H., Kimball B.P., Williams W.G., Hypertrophic cardiomyopathy. Clinical spectrum and treatment, Circulation, 92, pp. 1680-1692, (1995)
[2] Spirito P., Seidman C.E., McKenna W.J., Maron B.J., The management of hypertrophic cardiomyopathy, N. Engl. J. Med., 336, pp. 775-785, (1997)
[3] Maron B.J., Hypertrophic cardiomyopathy. A systematic review, JAMA, 287, pp. 1308-1320, (2002)
[4] Seidman J.G., Seidman C., The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms, Cell, 104, pp. 557-567, (2001)
[5] Maron B.J., McKenna W.J., Danielson G.K., Et al., A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, J. Am. Coll. Cardiol., 42, pp. 1687-1713, (2003)
[6] Elliott P., McKenna W.J., Hypertrophic cardiomyopathy, Lancet, 363, pp. 1881-1891, (2004)
[7] Maron B.J., Shen W.K., Link M.S., Et al., Efficacy of implantable-cardioverter defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N. Engl. J. Med., 342, pp. 365-373, (2000)
[8] Elliott P.M., Poloniecki J., Dickie S., Et al., Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients, J. Am. Cardiol., 36, pp. 2212-2218, (2000)
[9] Spirito P., Bellone P., Harris K.M., Et al., Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy, N. Engl. J. Med., 342, pp. 1778-1785, (2000)
[10] Monserrat L., Elliott P.M., Gimeno J.R., Et al., Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients, J. Am. Coll. Cardiol., 42, pp. 873-879, (2003)

← 1 2 3 →